Microbix Assisting EMQN with Novel Genetic-Test EQA Program
For Rapid Identification of Patients Susceptible to Antibiotic-Induced Hearing Loss MISSISSAUGA, CANADA & MANCHESTER, UK – December 10, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the […]
EMQN launches new EQA scheme for MT-RNR1 Point-of-Care Testing (POCT) for use with the Genedrive® MT-RNR1 ID Kit
EMQN CIC is pleased to announce the launch of a new EQA scheme for MT-RNR1 Point-of-Care Testing (POCT), suitable for use with the NICE-approved Genedrive® MT-RNR1 ID Kit. This scheme is designed to support the accurate identification of patients in acute clinical settings who carry the MT-RNR1 m.1555A>G variant, ensuring they receive alternative antibiotics to prevent hearing loss. This […]
Webinar: Rapid Point-of-Care Testing: The Next Frontier in Pharmacogenomics by John McDermott
Dr John McDermott is a Clinical Geneticist and an NIHR Doctoral Research Fellow at the University of Manchester. He was the UK’s first Academic Clinical Fellow in Genomic Medicine. Working at the Manchester Centre for Genomic Medicine his research focuses on the application of genomics in acute and everyday healthcare settings. He has recently been […]
Enhancing Point-of-Care Testing (POCT): EMQN CIC to introduce innovative EQA Scheme for MT-RNR1 m.1555A>G POCT
As the healthcare landscape has begun to rely increasingly on the use of point-of-care testing at, or close to, the patient’s bedside, it is crucial to ensure those tests are accurate and reliable, since immediate clinical decisions are based on the outcomes where even the slightest error could have profound consequences. EMQN CIC has introduced […]
